Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
105 hedge funds and large institutions have $145M invested in Inozyme Pharma in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 17
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
18% more funds holding
Funds holding: 89 → 105 (+16)
5.46% less ownership
Funds ownership: 87.02% → 81.56% (-5.5%)
49% less capital invested
Capital invested by funds: $286M → $145M (-$140M)
53% less call options, than puts
Call options by funds: $7K | Put options by funds: $15K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$4.37M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.16M |
| 3 |
BlackRock
New York
|
+$1.22M |
| 4 |
Renaissance Technologies
New York
|
+$976K |
| 5 |
Walleye Capital
New York
|
+$904K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$17M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.28M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.49M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.95M |
| 5 |
Goldman Sachs
New York
|
-$740K |
INZY Hedge Fund Activity: Q4 2024 in Review
105 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2024, worth a combined $145M — down 49% from $286M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new INZY positions and 19 closed out — a net gain of 16 holders — while 34 added to existing stakes and 17 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $4.37M. The largest seller was Samlyn Capital, exiting entirely with an estimated $17M sold.
- 105 institutional investors held Inozyme Pharma (INZY) as of Q4 2024, up from 89 in Q3 2024.
- Funds reported $145M of Inozyme Pharma stock for Q4 2024, down 49% quarter-over-quarter.
- 35 funds opened new Inozyme Pharma positions in Q4 2024 and 19 closed out, a net change of +16 holders.
- The largest Inozyme Pharma buyer in Q4 2024 was Affinity Asset Advisors, an estimated $4.37M added.
- The largest Inozyme Pharma seller in Q4 2024 was Samlyn Capital, an estimated $17M sold.
Based on aggregated 13F filings for Q4 2024.